Last updated: April 15, 2026

Application No. 18/114,981

ENGINEERED IMMUNE CELLS WITH PRIMING RECEPTORS

Non-Final OA

Filed

Feb 27, 2023

Examiner

KIM, YUNSOO

Art Unit

1641

Tech Center

1600 — Biotechnology & Organic Chemistry

Assignee

Arsenal Biosciences, INC.

OA Round

1 (Non-Final)

Interview Optional

— +18.0% interview lift. This examiner has a relatively high allow rate; a written response may suffice.

Based on 914 resolved cases, 2023–2026

Examiner Intelligence

KIM, YUNSOO View full profile →

Grants 66% — above average

Career Allow Rate

600 granted / 914 resolved

+5.6% vs TC avg

Strong +18% interview lift

Without

With

+18.0%

Interview Lift

resolved cases with interview

Typical timeline

3y 7m

Avg Prosecution

62 currently pending

Career history

976

Total Applications

across all art units

Statute-Specific Performance

§101

0.1%

-39.9% vs TC avg

§103

37.1%

-2.9% vs TC avg

§102

6.6%

-33.4% vs TC avg

§112

12.5%

-27.5% vs TC avg

Black line = Tech Center average estimate • Based on career data from 914 resolved cases

Prosecution Timeline

Feb 27, 2023

Application Filed

Sep 08, 2025

Non-Final Rejection

Apr 13, 2026

Response after Non-Final Action

Precedent Cases

Applications granted by this same examiner with similar technology

16/298,474

Patent 12582716

STABLE, AQUEOUS FORMULATIONS OF ANTIBODIES THAT BIND IL5 RECEPTOR

2y 5m to grant Granted Mar 24, 2026

19/198,946

Patent 12583936

Subcutaneous Formulations Of Anti-CD38 Antibodies And Their Uses

2y 5m to grant Granted Mar 24, 2026

16/882,280

Patent 12559551

STABILIZED FORMULATIONS CONTAINING ANTI-ANGPTL3 ANTIBODIES

2y 5m to grant Granted Feb 24, 2026

17/864,622

Patent 12558422

Immunoglobulin Preparation and Storage System for an Immunoglobulin Preparation

2y 5m to grant Granted Feb 24, 2026

17/926,313

Patent 12558423

ANTIBODY-CONTAINING FORMULATION

2y 5m to grant Granted Feb 24, 2026

Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.

Prosecution Projections

1-2

Expected OA Rounds

66%

Grant Probability

84%

With Interview (+18.0%)

3y 7m

Median Time to Grant

Low

PTA Risk

Based on 914 resolved cases by this examiner. Grant probability derived from career allow rate.

ENGINEERED IMMUNE CELLS WITH PRIMING RECEPTORS

Interview Optional

Examiner Intelligence

Statute-Specific Performance

Prosecution Timeline

Precedent Cases

Applications granted by this same examiner with similar technology

AI Strategy Recommendation

Prosecution Projections

Ready to respond to this office action?

Sign in for Full Analysis